CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed Net Margin across 11 years of filings, most recently posting 8431.48% for Q1 2026.

• Net Margin for Q1 2026 came in at 8431.48%, up 729060.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1021.94% (up 97490.0% YoY), and the FY2025 annual result was 823.16%, up 72357.0% from the prior year.
• Net Margin came in at 8431.48% for Q1 2026 at CRISPR Therapeutics AG, down from 55539.24% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 55539.24% in Q4 2025 to a low of 1842100.0% in Q4 2022.
• The 5-year median for Net Margin is 15001.07% (2024), against an average of 139334.89%.
• Across the five-year window, Net Margin slumped 184096955 bps in 2022 and surged 184214420 bps in 2023, its largest moves.
• CRISPR Therapeutics AG's Net Margin stood at 1842100.0% in 2022, then jumped by 100 bps to 44.2% in 2023, then soared by 2221 bps to 1025.75% in 2024, then soared by 5314 bps to 55539.24% in 2025, then sank by 115 bps to 8431.48% in 2026.
• The last three Net Margin figures came in at 8431.48% (Q1 2026), 55539.24% (Q4 2025), and 11973.12% (Q3 2025), per Business Quant data.